Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tg100-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG known ✓ | P48736 | 13/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | PDXK | O00764 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | OXSR1 | O95747 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tg100-115 SCHEMBL29506727 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL31238338 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29369340 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL360279 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29411790 | 1.00 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539255 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3537211 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539251 | 0.98 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL13403357 | 0.92 | PIK3CG (0.85) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3743017 | 0.91 | PIK3CG (0.82) | PIK3CGPIK3CAPIK3CBMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1011 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2025217056-A2 | VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) RECEPTOR ANTAGONISTS FC FUSIONS AND METHODS OF USE | CAMBIUM ONCOLOGY (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4554595-A2 | GALPHA12 INHIBITORS AND METHODS USING SAME | Rutgers, the State University of New Jersey (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | claimed |
| WO-2022100659-A1 | COMBINATION THERAPY AND METHODS UTILIZING THE SAME | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2022-05-19 | — | — | WO | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| CN-114099682-A | Application of PI3K gamma inhibitor in treating radiofrequency ablation residual tumor | 中山大学孙逸仙纪念医院 | 2022-03-01 | — | — | CN | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| US-11246907-B2 | Immunosuppressive agents and their use in therapy | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NO) | 2022-02-15 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | BRAF, TTK, CKS1B | PIK3CG 1122/4885PIK3CD 750/4885PIK3CA 1029/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PIK3CG 61/4885PIK3CD 18/4885PIK3CA 13/4885 |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | PARP2, DOCK2, DYNLL2 | PIK3CG 148/4885PIK3CD 47/4885PIK3CA 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.